Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stromal cells (MSCs) are a type of multipotent cell therapy being evaluated by the Guangdong Provincial People's Hospital for the treatment of chronic graft-versus-host disease (cGvHD). MSCs possess unique immunomodulatory properties, allowing them to migrate to sites of inflammation and suppress the activity of various immune cells, including T-cells, B-cells, and natural killer cells, which are responsible for the pathogenesis of cGvHD. In clinical trials, these cells are typically administered intravenously as an adjunct to standard immunosuppressive regimens, such as corticosteroids and calcineurin inhibitors, to improve response rates and reduce the severity of the disease in newly diagnosed or steroid-refractory patients. This specific MSC product is currently being evaluated in a Phase III randomized, open-label, multi-center study in Southern China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesenchymal stromal cells.